AYTU
AYTU BIOPHARMA, INCCompany Information
- Company Name
- AYTU BIOPHARMA, INC
- CIK
- CIK0001385818
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- AYTU: Nasdaq
- Fiscal Year End
- June 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AYTU
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-06-09
- Last sale
- —
- Shares purchased (TTM)
- 98,332
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 7,903,035
- Shares outstanding
- 12,318,817
- Ownership
- 64.15%
Earnings Market Reaction
- Filing date
- 2026-09-22
- Price on filing date
- —
- 1-month reaction
- Pending
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 26 | 27 | 30 | 33 | 31 | 18 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Accounts Receivable Net Current | 23 | 24 | 31 | 33 | 31 | 36 | 25 | 23 | 24 | 30 | 29 | 30 | ||||||
| Inventory Net | 7 | 7 | 9 | 10 | 11 | 11 | 11 | 12 | 12 | 13 | 13 | 13 | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | 6 | 6 | 6 | 7 | 8 | 7 | ||||||
| Prepaid Expense And Other Assets Current | 6 | 9 | 7 | 5 | 6 | 7 | - | - | 5 | - | - | - | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | 0 | 0 | 0 | 0 | 1 | - | - | - | ||||||
| Assets Current | 62 | 67 | 76 | 81 | 79 | 73 | - | - | 62 | 71 | 71 | 71 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Other Assets Current | - | - | - | - | - | - | 63 | 61 | 62 | 1 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Intangible Assets Net Excluding Goodwill | 41 | 42 | 44 | 41 | 42 | 49 | 50 | 51 | 52 | 54 | 56 | 57 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | ||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Assets Noncurrent | 43 | 44 | 46 | 44 | 45 | 52 | 53 | 55 | 56 | 58 | 60 | 62 | ||||||
| Assets | 105 | 112 | 122 | 125 | 124 | 124 | 116 | 116 | 118 | 129 | 131 | 133 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Other Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | - | - | 14 | ||||||
| Accounts Payable Current | 11 | 13 | 14 | 12 | 11 | 12 | 12 | 14 | 10 | 10 | 10 | - | ||||||
| Accrued Liabilities Current | 35 | 34 | 40 | 37 | 38 | 42 | 39 | 34 | 38 | 44 | 43 | 41 | ||||||
| Short Term Borrowings | - | - | - | - | - | - | 4 | 4 | 2 | 2 | 1 | 1 | ||||||
| Long Term Debt Current | - | - | - | - | - | - | 2 | 2 | 2 | 15 | 0 | - | ||||||
| Derivative Liabilities Current | - | - | - | - | - | - | - | - | - | 3 | - | - | ||||||
| Lines Of Credit Current | 6 | 10 | 9 | 15 | 9 | 10 | - | - | 2 | - | - | - | ||||||
| Long Term Debt And Capital Lease Obligations Current | 2 | 2 | 2 | 2 | 2 | 2 | - | - | 2 | - | - | 0 | ||||||
| Other Liabilities Current | 0 | 0 | 0 | 0 | 3 | 5 | 7 | 8 | 9 | 9 | 9 | 9 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | 0 | 0 | 0 | 0 | 1 | - | - | - | ||||||
| Liabilities Current | 55 | 60 | 66 | 66 | 63 | 71 | 64 | 61 | 62 | 84 | 64 | 65 | ||||||
| Long Term Debt Noncurrent | - | - | - | - | - | - | 10 | 10 | 11 | 0 | 15 | - | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Long Term Debt And Capital Lease Obligations | 9 | 10 | 10 | 10 | 11 | 10 | - | - | 11 | - | - | 15 | ||||||
| Derivative Liabilities Noncurrent | 1 | 2 | 27 | 20 | 26 | 4 | 6 | 9 | 13 | 9 | 13 | 12 | ||||||
| Other Liabilities Noncurrent | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 8 | ||||||
| Liabilities | - | - | - | - | - | - | - | - | - | - | - | 101 | ||||||
| Liabilities Noncurrent | 15 | 17 | 42 | 36 | 42 | 19 | 21 | 25 | 28 | 14 | 34 | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 383 | 383 | 356 | 355 | 353 | 349 | 348 | 348 | 348 | 346 | 345 | 344 | ||||||
| Retained Earnings Accumulated Deficit | -348 | -348 | -342 | -332 | -334 | -314 | -318 | -318 | -320 | -315 | -312 | -312 | ||||||
| Stockholders Equity | 35 | 35 | 14 | 23 | 19 | 35 | 31 | 30 | 28 | 31 | 33 | 32 | ||||||
Preferred Stock Number Of Shares Par Value And Other Disclosures | ||||||||||||||||||
| Liabilities And Stockholders Equity | 105 | 112 | 122 | 125 | 124 | 124 | 116 | 116 | 118 | 129 | 131 | 133 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Common Stock Number Of Shares Par Value And Other Disclosures | ||||||||||||||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 11 | 11 | 11 | 10 | 9 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | ||||||
| Shares Outstanding | 11 | 11 | 11 | 10 | 9 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAYTU BIOPHARMA, INC (AYTU) — SEC Financial Statements & Analysis
AYTU BIOPHARMA, INC (AYTU) is a pharmaceutical preparations company, incorporated in DE. AYTU BIOPHARMA, INC trades on Nasdaq as: AYTU. AYTU BIOPHARMA, INC (AYTU)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-09-22. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), AYTU BIOPHARMA, INC carries a market cap of $26.49M, a P/E ratio of -1.86x, a P/B ratio of 0.75x, a P/S ratio of 0.46x, an enterprise value of $17.21M, and an EV/EBITDA multiple of -2.96x. On profitability, it posts a gross margin of 63.95%, an operating margin of -14.44%, a net margin of -24.76%, a Return on Equity (ROE) of -52.55%, a Return on Assets (ROA) of -12.44%, and a Return on Invested Capital (ROIC) of -43.35%. Per share, it reports EPS of $-1.16, diluted EPS of $-3.24, free cash flow per share of $0.26, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -13.27% year-over-year, net income growth of 5.09% year-over-year, and EPS growth of -46.43% year-over-year. On the balance sheet, it maintains a current ratio of 1.13x, a quick ratio of 0.90x, working capital of $7.10M, a debt-to-equity ratio of 1.98x, a debt ratio of 0.66, an interest coverage ratio of -4.39x, free cash flow of $3.22M (TTM), and net debt of $-9.28M. Figures sourced from SEC EDGAR.
- Market Cap
- $26.49M
- P/E TTM
- -1.86x
- EPS TTM
- $-1.16
- P/B TTM
- 0.75x
- ROE TTM
- -52.55%
- ROA TTM
- -12.44%
- Debt To Equity
- 1.98x
- Free Cash Flow TTM
- $3.22M
- Net Revenue TTM Growth 1Y
- -13.27%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is AYTU BIOPHARMA, INC in?
AYTU BIOPHARMA, INC (AYTU) operates in the Pharmaceutical Preparations industry.
What exchange does AYTU trade on?
AYTU BIOPHARMA, INC (AYTU) trades on the Nasdaq.
Where is AYTU BIOPHARMA, INC incorporated?
AYTU BIOPHARMA, INC is incorporated in DE.
When was AYTU BIOPHARMA, INC (AYTU)'s most recent SEC filing?
AYTU BIOPHARMA, INC (AYTU)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-09-22.
What is AYTU's market cap?
AYTU BIOPHARMA, INC (AYTU) has a market capitalization of $26.49M as of 2026-06-30.
What is AYTU's EPS (earnings per share)?
AYTU BIOPHARMA, INC (AYTU)'s trailing twelve month EPS is $-1.16 as of 2026-06-30.
What is AYTU's ROE (return on equity)?
AYTU BIOPHARMA, INC (AYTU)'s trailing twelve month Return on Equity (ROE) is -52.55% as of 2026-06-30.
What is AYTU's ROA (return on assets)?
AYTU BIOPHARMA, INC (AYTU)'s trailing twelve month Return on Assets (ROA) is -12.44% as of 2026-06-30.
What is AYTU's ROIC (return on invested capital)?
AYTU BIOPHARMA, INC (AYTU)'s trailing twelve month Return on Invested Capital (ROIC) is -43.35% as of 2026-06-30.
What is AYTU's EV/EBITDA?
AYTU BIOPHARMA, INC (AYTU)'s trailing twelve month EV/EBITDA is -2.96x as of 2026-06-30.